Antipsychotic medicines cause obesity and diabetes

In 2008, roughly 14.3 million Americans were taking antipsychotics—typically prescribed for bipolar disorder, schizophrenia, or a number of other behavioral disorders—making them among the most prescribed drugs in the U.S. Almost all of these medications are known to cause the metabolic side effects of obesity and diabetes, leaving patients with a difficult choice between improving their mental health and damaging their physical health.

continue reading

H1N1 flu :: Pandemic swine flu – H1N1 Influenza

Novel H1N1 (referred to as “swine flu” early on) is a new influenza virus causing illness in people. This new virus was first detected in people in the United States in April 2009. Other countries, including Mexico and Canada, have reported people sick with this new virus. This virus is spreading from person-to-person, probably in much the same way that regular seasonal influenza viruses spread.

MRSA :: Factor key to severity of community-associated methicillin-resistant staph infections identified

Newly described proteins in drug-resistant strains of the Staphylococcus aureus bacterium attract and then destroy protective human white blood cells—a key process ensuring that S. aureus survives and causes severe disease, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Multiple Sclerosis :: Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease

An immune system messenger molecule that normally helps quiet inflammation could be an effective tool against multiple sclerosis (MS). Neurology researchers led by Abdolmohamad Rostami, M.D., Ph.D., professor and chair of the Department of Neurology at Jefferson Medical College of Thomas Jefferson University and the Jefferson Hospital for Neuroscience in Philadelphia, have found that the protein interkeukin-27 (IL-27) helped block the onset or reverse symptoms in animals with an MS-like disease.

Lupus :: Existing drugs show promise for treating end-stage renal disease in lupus

Studies in mice suggest that two drugs already approved by the U.S. Food and Drug Administration show promise for treating the complications of lupus, according to Nilamadham Mishra, M.D., in presentations this week at the American College of Rheumatology in Boston.